Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Debate Continues Over Experimental Ebola Drugs

August 13, 2014 2:06 pm | by Sarah Dilorenzo and Maria Cheng, Associated Press | News | Comments

Doctors treating a leading Sierra Leone physician who became sick with Ebola considered giving him an experimental drug but feared it could trigger a dangerous immune response and did not administer it, Doctors Without Borders said Wednesday. Read more...

TOPICS:

Epizyme Presents Early-Phase Data on Cancer Drug

August 13, 2014 11:24 am | News | Comments

Epizyme Inc. reported pre-clinical data and early clinical observations from an ongoing Phase 1 trial, being conducted in collaboration with Eisai, the Institut Gustave Roussy, and the Institut Bergonie, of EZH2 inhibitor EPZ-6438 (E7438) in patients with advanced solid tumors and B-cell lymphomas. Read more...

TOPICS:

TNI BioTech, Hubei Qianjiang Agree to Collaborate

August 13, 2014 11:17 am | News | Comments

TNI BioTech Inc. a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, announced the signing of a supplemental agreement with Hubei Qianjiang Pharmaceutical Co. Ltd, China, on behalf of Cytocom, TNI BioTech's wholly owned subsidiary. Read more...

TOPICS:
Advertisement

AstraZeneca’s Gout Drug Achieves Positive Results

August 13, 2014 11:12 am | News | Comments

AstraZeneca announced positive top-line results from CLEAR1, CLEAR2 and CRYSTAL, the pivotal Phase 3 clinical trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), as a combination therapy for the treatment of patients with symptomatic gout. Read more...

TOPICS:

Pfizer Posts Mixed Results from Chinese Lyrica Studies

August 13, 2014 11:08 am | News | Comments

Pfizer Inc. announced top-line results from two placebo-controlled studies conducted in China with Lyrica (pregabalin) in patients with postherpetic neuralgia (pain after shingles or PHN) and painful diabetic peripheral neuropathy (pDPN), respectively. Read more...

TOPICS:

Meta-Analysis Approach May Affect Conclusion

August 13, 2014 11:02 am | News | Comments

Depending on the analysis strategy used, estimating treatment outcomes in meta-analyses may differ and may result in major alterations in the conclusions derived from the analysis, according to a study in the August 13 issue of JAMA. Read more...

TOPICS:

UN: OK to Use Untested Ebola Drugs in Outbreak

August 13, 2014 10:57 am | by Maria Cheng, Ciaran Giles, Associated Press | News | Comments

The World Health Organization declared it's ethical to use untested drugs and vaccines in the ongoing Ebola outbreak in West Africa, although the tiny supply of one experimental treatment has been depleted and it could be many months until more is available. Read more...

TOPICS:

MJFF Highlights Promising Parkinson's Disease Drug Research

August 12, 2014 3:21 pm | News | Comments

Research projects from five groups active in Parkinson's research comprise the 2014 first half (1H 2014) of The Michael J. Fox Foundation for Parkinson's Research (MJFF) Partnering Program. Read more...                

TOPICS:
Advertisement

Epigenetic Cancer Cell Markers Could Improve Treatment

August 12, 2014 3:05 pm | News | Comments

Scientists have known for decades that cancer can be caused by genetic mutations, but more recently they have discovered that chemical modifications of a gene can also contribute to cancer. These alterations, known as epigenetic modifications, control whether a gene is turned on or off. Now, a team engineers has developed a fast, reliable method to detect this type of modification. Read more...

TOPICS:

Long-Sought Drug Candidate Can Halt Tumor Growth

August 12, 2014 2:50 pm | News | Comments

It’s a trick any cat burglar knows: to open a locked door, slide a credit card past the latch. Scientists tried a similar strategy when they attempted to disrupt the function of MYC, a cancer regulator thought to be “undruggable." Read more...   

TOPICS:

Clinical Trial Evaluates Safety of Stem Cell Transplantation in Spine

August 12, 2014 2:41 pm | Videos | Comments

Researchers have launched a clinical trial to investigate the safety of neural stem cell transplantation in patients with chronic spinal cord injuries. This Phase 1 clinical trial is recruiting eight patients for the five-year study. Read more...

TOPICS:

Ebola: Questions, Answers About Unproven Drug

August 12, 2014 2:25 pm | by Lauran Neergaard, AP Medical Writer | News | Comments

An experimental Ebola drug has been used to treat two American aid workers and a Spanish missionary priest, and the Liberian government said that it will receive doses of the drug to treat two doctors in the country. Read more...       

TOPICS:

Cortendo Enrolls First Patient into Cushing’s Study

August 12, 2014 11:43 am | News | Comments

Cortendo AB announced that the first patient has been enrolled into the Phase 3 SONICS trial, i.e., “Study of NormoCort in Cushing’s Syndrome,” after successfully completing its European Investigator meeting supporting SONICS. Read more...

TOPICS:

Prosensa, CureDuchenne Strengthen Collaboration

August 12, 2014 11:38 am | News | Comments

Prosensa Holding N.V. announced that an affiliate of CureDuchenne will provide Prosensa with up to €5 million by means of convertible promissory notes to support the company and accelerate the development and patient access of much needed DMD therapies. Read more...

TOPICS:

Sanofi Launches Generic Eloxatin

August 12, 2014 11:31 am | News | Comments

Sanofi US announced that it has launched an authorized generic version of Eloxatin (oxaliplatin injection) through Winthrop US, the company's generics division. Sanofi's authorized generic version is the same formulation as the original drug, Eloxatin, for which the company holds the original patent. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading